{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:19:20Z","timestamp":1788153560785,"version":"build-2803163510"},"reference-count":82,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Spanish Ministry of Science","award":["PI20\/00137"],"award-info":[{"award-number":["PI20\/00137"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI20\/00106"],"award-info":[{"award-number":["PI20\/00106"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"award":["PI20\/00106"],"award-info":[{"award-number":["PI20\/00106"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}]},{"name":"GILEAD Sciences","award":["GLD19\/00008"],"award-info":[{"award-number":["GLD19\/00008"]}]},{"award":["GLD19\/00008"],"award-info":[{"award-number":["GLD19\/00008"]}],"id":[{"id":"https:\/\/ror.org\/02qacef07","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>The spectrum of diseases in individuals with human immunodeficiency virus (HIV) receiving successful antiretroviral therapy has evolved over time. In the past, they developed opportunistic infections and malignancies, whereas today, cardiovascular disease is among the most common causes of illness and premature death. Traditional risk factors for atherosclerosis (hypertension, hyperlipidemia, smoking, diabetes, family history of heart disease) are more prevalent in people with HIV than in the general population. However, it is well established that HIV itself causes increased immune activation, chronic inflammation, vascular dysfunction, and a cluster of metabolic abnormalities that contribute to a faster-than-usual rate of biological aging and a higher risk of developing atherosclerosis, a risk not fully captured by current risk models. In the REPRIEVE study, treatment with pitavastatin was shown to reduce the rate of first cardiovascular events among individuals with HIV receiving antiretroviral therapy. Importantly, the beneficial effects of statins on atherosclerosis likely extend beyond lowering cholesterol to include effects on vascular function and on immune and metabolic systems altered by HIV. Even among individuals on statins, a considerable risk of cardiovascular disease remains. Here, We provide a narrative review of current evidence and an expert perspective on emerging approaches to residual cardiovascular risk after REPRIEVE. We review the current understanding of atherosclerosis pathogenesis in individuals with HIV, focusing on recent findings from the REPRIEVE trial. We outline current approaches to improving cardiovascular risk assessment across clinical, biological, and computational levels. We also examine a growing number of therapeutic options that address residual inflammation and atherogenic metabolic disturbance in individuals with HIV on long-term, effective antiretroviral therapy. Significantly, after REPRIEVE, we must move from prescribing statins to all individuals with HIV toward more individualized cardiovascular disease prevention strategies, integrating clinical information, a variety of biomarkers, imaging studies, and even molecular information to generate optimal individualized cardiovascular disease prevention regimens that reflect the complexity of this outcome in naturally diverse individuals.<\/jats:p>","DOI":"10.3390\/biom16091254","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:08:58Z","timestamp":1788142138000},"page":"1254","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Lipid Lowering: A Narrative Review and Expert Perspective on Precision Cardiovascular Prevention in People with HIV After REPRIEVE"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-5770","authenticated-orcid":false,"given":"Pere","family":"Domingo","sequence":"first","affiliation":[{"name":"Malalties Infeccioses, Hospital de la Santa Creu i Sant Pau, Sant Quint\u00ed, 41-49, 08041 Barcelona, Spain"},{"name":"Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Reial Acad\u00e8mia de Medicina de Catalunya, 08001 Barcelona, Spain"},{"name":"Departament de Medicina, Universitat Aut\u00f2noma de Barcelona, 08023 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1978-758X","authenticated-orcid":false,"given":"Paula","family":"Prieto","sequence":"additional","affiliation":[{"name":"Malalties Infeccioses, Hospital de la Santa Creu i Sant Pau, Sant Quint\u00ed, 41-49, 08041 Barcelona, Spain"},{"name":"Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Reial Acad\u00e8mia de Medicina de Catalunya, 08001 Barcelona, Spain"},{"name":"Departament de Medicina, Universitat Aut\u00f2noma de Barcelona, 08023 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e295\u2013307","DOI":"10.1016\/S2352-3018(23)00028-0","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: A collaborative analysis of cohort studies","volume":"10","author":"Trickey","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2352-3018(26)00052-4","article-title":"Trends in AIDS-defining illnesses among people living with HIV in clinical care in Europe: Results from the EuroSIDA multicentre cohort study (2003-24)","volume":"13","author":"Bannister","year":"2026","journal-title":"Lancet HIV"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S2352-3018(20)30036-9","article-title":"HIV and cardiovascular disease","volume":"7","author":"Benjamin","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1161\/CIR.0000000000000695","article-title":"Characteristics, Prevention, and Management of Cardiovascular Disease in People Living with HIV: A Scientific Statement from the American Heart Association","volume":"140","author":"Feinstein","year":"2019","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1161\/CIRCULATIONAHA.117.028975","article-title":"Cardiovascular risk prediction functions underestimate risk in HIV infection","volume":"137","author":"Triant","year":"2018","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2411159","DOI":"10.1001\/jamanetworkopen.2024.11159","article-title":"Clinical Outcomes After Acute Coronary Syndromes or Revascularization Among People Living with HIV: A Systematic Review and Meta-Analysis","volume":"7","author":"Haji","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2013.10.001","article-title":"Systemic effects of inflammation on health during chronic HIV infection","volume":"39","author":"Deeks","year":"2013","journal-title":"Immunity"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1093\/eurheartj\/eht388","article-title":"HIV and the heart: The impact of antiretroviral therapy: A global perspective","volume":"34","author":"Thienemann","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/COH.0000000000000755","article-title":"HIV and cardiovascular disease: The role of inflammation","volume":"17","author":"Funderburg","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1161\/CIRCRESAHA.124.323891","article-title":"Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease","volume":"134","author":"Obare","year":"2024","journal-title":"Circ. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/CIRCULATIONAHA.122.057443","article-title":"Cardiovascular Disease Among Persons Living with HIV: New Insights into Pathogenesis and Clinical Manifestations in a Global Context","volume":"147","author":"Ntsekhe","year":"2023","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1097\/QAD.0b013e32835eca9b","article-title":"Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men","volume":"27","author":"Zanni","year":"2013","journal-title":"AIDS"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin and Cardiovascular Disease in HIV","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1056\/NEJMc2400870","article-title":"Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection","volume":"390","author":"Grinspoon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to Prevent Cardiovascular Disease in HIV Infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/jamacardio.2023.5661","article-title":"Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial","volume":"9","author":"Lu","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/clinchem\/hvad204","article-title":"An Old Drug Learning New Tricks: A REPRIEVE for Cardiovascular Disease in HIV Infection","volume":"70","author":"Sviridov","year":"2024","journal-title":"Clin. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"847","DOI":"10.7326\/ANNALS-24-03564","article-title":"Statin Therapy as Primary Prevention for Persons with HIV: A Synopsis of Recommendations from the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel","volume":"178","author":"Beavers","year":"2025","journal-title":"Ann. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1016\/S2352-3018(25)00047-5","article-title":"Statin use in HIV: European AIDS Clinical Society guidance for the primary prevention of cardiovascular disease","volume":"12","author":"Alagaratnam","year":"2025","journal-title":"Lancet HIV"},{"key":"ref_21","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2026, August 06). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV: Statin Therapy in People with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/statin-therapy-people-hiv."},{"key":"ref_22","unstructured":"British HIV Association (2026, August 06). BHIVA Guidance on the Use of Statins for Primary Prevention of Cardiovascular Disease in People Living with HIV. Available online: https:\/\/bhiva.org\/clinical-guideline\/statins-guidance\/."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamacardio.2022.4873","article-title":"Performance of Cardiovascular Risk Prediction Models Among People Living with HIV: A Systematic Review and Meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/S2352-3018(24)00276-5","article-title":"Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: A cohort study leveraging data from REPRIEVE","volume":"12","author":"Grinspoon","year":"2025","journal-title":"Lancet HIV"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"120743","DOI":"10.1016\/j.atherosclerosis.2026.120743","article-title":"Precision and network medicine in cardiovascular prevention and disease","volume":"417","author":"Pandey","year":"2026","journal-title":"Atherosclerosis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11904-018-0400-5","article-title":"HIV and Cardiovascular Disease: Update on Clinical Events, Special Populations, and Novel Biomarkers","volume":"15","author":"Freiberg","year":"2018","journal-title":"Curr. HIV AIDS Rep."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Vos, A.G., Hulzebosch, A., Grobbee, D.E., Barth, R.E., and Klipstein-Grobusch, K. (2017). Association between immune markers and surrogate markers of cardiovascular disease in HIV positive patients: A systematic review. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169986"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/infdis\/jir520","article-title":"Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients","volume":"204","author":"Burdo","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1016\/j.ijcard.2013.06.059","article-title":"Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy","volume":"168","author":"Longenecker","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/QAD.0000000000000158","article-title":"Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection","volume":"28","author":"Longenecker","year":"2014","journal-title":"AIDS"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiq118","article-title":"Plasma levels of soluble CD14 independently predict mortality in HIV infection","volume":"203","author":"Sandler","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/QAD.0000000000000885","article-title":"Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV","volume":"30","author":"Hileman","year":"2016","journal-title":"AIDS"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1161\/ATVBAHA.114.303887","article-title":"Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes","volume":"34","author":"Bekkering","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.20411\/pai.v5i1.365","article-title":"Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop","volume":"5","author":"Gabuzda","year":"2020","journal-title":"Pathog. Immun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/QAD.0000000000002063","article-title":"Do people living with HIV experience greater age advancement than their HIV-negative counterparts?","volume":"33","author":"Wit","year":"2019","journal-title":"AIDS"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11904-023-00646-0","article-title":"Biological Aging in People Living with HIV on Successful Antiretroviral Therapy: Do They Age Faster?","volume":"20","author":"Neogi","year":"2023","journal-title":"Curr. HIV AIDS Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic Effects of Statins on the Cardiovascular System","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1097\/QAD.0000000000001109","article-title":"Inflammation, immune activation, and cardiovascular disease in HIV","volume":"30","author":"Nou","year":"2016","journal-title":"AIDS"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2352-3018(14)00032-0","article-title":"Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: A randomised, double-blind, placebo-controlled trial","volume":"2","author":"Lo","year":"2015","journal-title":"Lancet HIV"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3851\/IMP3389","article-title":"Statin effect on coronary calcium distribution, mass and volume scores and associations with immune activation among HIV+ persons on antiretroviral therapy","volume":"25","author":"Lipinski","year":"2020","journal-title":"Antivir. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e26525","DOI":"10.1002\/jia2.26525","article-title":"REPRIEVE final results: What does it mean for guidelines in low- and middle-income countries?","volume":"28","author":"Sokhela","year":"2025","journal-title":"J. Int. AIDS Soc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/cid\/ciad702","article-title":"From Evidence to Effectiveness: Implications of the Randomized Trial to Prevent Vascular Events in HIV Study for People with HIV in Low- and Middle-Income Settings","volume":"78","author":"Ali","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/infdis\/jiq115","article-title":"High-dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: Results of a double-blind randomized placebo controlled clinical trial","volume":"203","author":"Ganesan","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9661752","DOI":"10.1155\/2021\/9661752","article-title":"The effects of statin dose, lipophilicity, and combination of statins plus ezetimibe on circulating oxidized low-density lipoprotein levels: A systematic review and meta-analysis of randomized controlled trials","volume":"2021","author":"Jamialahmadi","year":"2021","journal-title":"Mediat. Inflamm."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cell.2017.11.025","article-title":"Metabolic Induction of Trained Immunity through the Mevalonate Pathway","volume":"172","author":"Bekkering","year":"2018","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/cid\/ciae422","article-title":"Pitavastatin Is Well-Tolerated with no Detrimental Effects on Physical Function","volume":"80","author":"Erlandson","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1097\/QAD.0000000000004306","article-title":"No evidence of pitavastatin effect on muscle area or density among people with HIV","volume":"39","author":"Erlandson","year":"2025","journal-title":"AIDS"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41598-021-04308-2","article-title":"Increased CHIP Prevalence Amongst People Living with HIV","volume":"12","author":"Bick","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Sinnadurai, S., Honigberg, M.C., Meijers, W.C., Merkus, D., Niroula, A., Sharma, H.S., Jankowski, P., Van Der Spek, P.J., de Boer, R.A., and Manintveld, O.C. (2026). Clonal Hematopoiesis in Cardiovascular Risk: Focus on Inflammatory Mechanisms. J. Clin. Med., 15.","DOI":"10.3390\/jcm15062393"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.125.075769","article-title":"Incorporating Management of Clonal Hematopoiesis of Indeterminate Potential into Cardiovascular Practice","volume":"152","author":"Oren","year":"2025","journal-title":"Circulation"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Anastasiou, I.A., Kounatidis, D., Vallianou, N.G., Rebelos, E., Karampela, I., and Dalamaga, M. (2025). Clonal Hematopoiesis of Indeterminate Potential and Cardiometabolic Disease: Challenges, Controversies and Future Perspectives. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27010233"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/ATVBAHA.125.322896","article-title":"Clonal Hematopoiesis and Major Adverse Cardiac Events in People with HIV: Insights from the REPRIEVE Trial","volume":"46","author":"Xue","year":"2026","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2012.6698","article-title":"Arterial inflammation in patients with HIV","volume":"308","author":"Subramanian","year":"2012","journal-title":"JAMA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41569-024-01009-x","article-title":"Uncovering atherosclerotic cardiovascular disease by PET imaging","volume":"21","author":"Maier","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ajpath.2023.12.007","article-title":"Omics Approaches Unveiling the Biology of Human Atherosclerotic Plaques","volume":"194","author":"Wu","year":"2024","journal-title":"Am. J. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e005451","DOI":"10.1161\/CIRCGEN.125.005451","article-title":"Multiomics for Risk Stratification in Atherosclerotic Cardiovascular Disease","volume":"19","author":"Nordestgaard","year":"2026","journal-title":"Circ. Genom. Precis. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"101511","DOI":"10.1016\/j.ajpc.2026.101511","article-title":"A machine learning-derived cardiovascular risk score in people with HIV: The ML-ICONA score","volume":"26","author":"Tavelli","year":"2026","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jacc.2018.12.036","article-title":"In Search of Patients with Elevated Lp(a): Seek and Ye Shall Find","volume":"73","author":"Tsimikas","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering with Pelacarsen on Major Cardiovascular Events in Patients with CVD and Elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am. Heart J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran\u2014A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jacc.2024.05.058","article-title":"The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results","volume":"84","author":"Rosenson","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41572-020-0197-6","article-title":"HIV and antiretroviral therapy-related fat alterations","volume":"6","author":"Koethe","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1161\/CIRCULATIONAHA.117.029617","article-title":"Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management","volume":"137","author":"Neeland","year":"2018","journal-title":"Circulation"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"ofaf152","DOI":"10.1093\/ofid\/ofaf152","article-title":"The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated Lipohypertrophy","volume":"12","author":"Funderburg","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1038\/s41467-026-72861-3","article-title":"Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy","volume":"17","author":"Corley","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S2213-8587(24)00150-5","article-title":"Once-weekly semaglutide in people with HIV-associated lipohypertrophy: A randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial","volume":"12","author":"Eckard","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and Validation of the American Heart Association\u2019s PREVENT Equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1093\/cid\/ciaf542","article-title":"Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2","volume":"82","author":"Grinspoon","year":"2026","journal-title":"Clin. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: Addressing the obverse side of the atherosclerosis prevention coin","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in Patients with Chronic Coronary Disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.immuni.2017.08.009","article-title":"Foundations of Immunometabolism and Implications for Metabolic Health and Disease","volume":"47","author":"Hotamisligil","year":"2017","journal-title":"Immunity"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1126\/science.aaf1098","article-title":"Trained immunity: A program of innate immune memory in health and disease","volume":"352","author":"Netea","year":"2016","journal-title":"Science"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial","volume":"7","author":"Svensson","year":"2022","journal-title":"JAMA Cardiol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/9\/1254\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:31:30Z","timestamp":1788150690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/9\/1254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":82,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["biom16091254"],"URL":"https:\/\/doi.org\/10.3390\/biom16091254","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}